Table 2.

Summary of the piecewise model predicting PTSD symptoms

	D-cycloserine		Alprazolam		Placebo
	CAPS	PSS	CAPS	PSS	CAPS	PSS
Baseline	85.3 (79.3–91.9)	32.9 (29.7–36.2)	88.0 (82.3–93.6)	32.4 (26.0–38.9)	82.6 (75.8–89.4)	32.4 (29.1–35.7)
Post-tx	65.9 (60.2–71.6)	27.1 (24.3–29.9)	69.6 (63.8–75.4)	25.6 (22.5–28.7)	63.8 (56.7–70.9)	24.2 (20.2–28.1)
3-month	60.3 (54.4–66.2)	25.2 (22.0–28.5)	66.8 (59.6–74.0)	26.1 (22.6–29.4)	51.5 (43.6–59.5)	21.4 (17.1–25.6)
6-month	56.00 (50.1–62.00)	24.1 (20.5–27.6)	63.4 (55.4–71.4)	26.3 (22.5–30.1)	46.9 (38.7–55.1)	20.0 (15.9–24.0)
12-month	48.0 (41.0–55.0)	22.6 (19.1–26.1)	57.2 (50.6–63.8)	24.2 (20.8–27.6)	48.4 (41.0–55.8)	21.7 (17.9–25.4)

Note: DCS = D-cycloserine; CAPS = Clinician Administered PTSD Scale; PSS = PTSD Symptom Scale; post-tx = post-treatment assessment; All of these value are point estimates with a corresponding confidence interval (CI). The CI is needed to provide a range for the population parameter estimate. The CI around the baseline measure indicates that all of the groups started at the same point.